Tzanakis N E, Peros G, Karakitsos P, Giannopoulos G A, Efstathiou S P, Rallis G, Tsigris Chr, Kostakis A, Nikiteas N I
4th Department of Surgery, Attikon Hospital, University of Athens, Athens, Greece.
Acta Chir Belg. 2009 Oct;109(5):606-11. doi: 10.1080/00015458.2009.11680496.
The variability of prognosis of gastric cancer (GC) within a pathological stage necessitates the identification of subgroups of patients with a more aggressive disease. The role of p53 and Ki67 expression in gastric carcinoma is far from being fully established. The aim of the present study was to evaluate the expression of p53 and Ki67 in gastric cancer and correlate the findings with several clinicopathological features and prognosis.
Tissue samples from 93 patients treated by gastric resection for gastric carcinoma between 1996 and 2001 were used. Formalin-fixed paraffin-embedded tumors were studied by immunohistochemistry, using monoclonal antibodies to p53 and Ki67. The results were correlated with clinicopathological features and survival.
Stronger expression of p53 was related with tumor size greater than 5 cm and advanced stage. Stronger expression of Ki67 correlated with higher ratio of the number of metastatic lymph nodes to the total number of dissected lymph nodes (metastatic lymph node [MLN] ratio) and advanced stage. Moreover, p53 and Ki67 overexpression, tumor size greater than 5 cm, MLN ratio, depth of invasion, lymph node metastasis, stage III and IV and infiltrative macroscopic appearance were adverse prognostic factors. The levels of p53 and Ki67, the MLN ratio, the tumor size (above 5 cm) and the stage of the disease were identified as independent prognostic factors of survival.
In gastric cancer, the expression of p53 and Ki67 provides significant information about prognosis. The routine evaluation of p53 and Ki67 levels could be a useful tool in identification of patient with more aggressive disease and contribute to a better therapeutic approach.
胃癌(GC)在病理分期内预后存在变异性,因此有必要识别疾病侵袭性更强的患者亚组。p53和Ki67表达在胃癌中的作用尚未完全明确。本研究的目的是评估p53和Ki67在胃癌中的表达,并将结果与多种临床病理特征及预后相关联。
使用1996年至2001年间接受胃癌胃切除术的93例患者的组织样本。采用免疫组织化学方法,使用针对p53和Ki67的单克隆抗体,对福尔马林固定石蜡包埋的肿瘤进行研究。将结果与临床病理特征及生存率相关联。
p53的更强表达与肿瘤大小大于5 cm及晚期相关。Ki67的更强表达与转移淋巴结数量与清扫淋巴结总数的比例(转移淋巴结[MLN]比例)较高及晚期相关。此外,p53和Ki67过表达、肿瘤大小大于5 cm、MLN比例、浸润深度、淋巴结转移、III期和IV期以及浸润性大体外观均为不良预后因素。p53和Ki67水平、MLN比例、肿瘤大小(5 cm以上)及疾病分期被确定为生存的独立预后因素。
在胃癌中,p53和Ki67的表达提供了有关预后的重要信息。常规评估p53和Ki67水平可能是识别侵袭性更强疾病患者的有用工具,并有助于采取更好的治疗方法。